Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2013-07-02 Board/Management Inform…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 2, 2013. The content focuses on the departure of a Chief Scientific Officer and appointment to the Scientific Advisory Board, along with related compensatory arrangements. There is no financial data or report content, but rather an announcement of management changes. This fits the category of Board/Management Information (MANG). The document length is 5608 characters, sufficient to contain substantive information about management changes. Therefore, the classification is MANG with high confidence.
2013-07-02 English
4
Director's Dealing
2013-07-01 English
424B3
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed by OvaScience, Inc. It includes announcements of the election of a new director to the board, appointment of a new officer, and details about director compensation policy. It also contains voting results from the 2013 annual meeting of stockholders. The content focuses on board and management changes and voting results rather than financial results or full reports. The presence of Item 5.02 (director and officer changes) and Item 5.07 (voting results) confirms this. Therefore, the document fits best under Board/Management Information (MANG) due to the director and officer appointments and also includes voting results, but since the voting results are part of the same report and not a standalone voting results announcement, MANG is the most appropriate classification. The document length and detail confirm it is not a brief announcement or a proxy solicitation. Confidence is high given the clear regulatory form and content.
2013-06-13 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed by OvaScience, Inc. It includes announcements of the election of a new director (Mary Fisher) and appointment of a new officer (Christopher M. Lindblom), details about their compensation, and voting results from the 2013 annual meeting of stockholders. The key content is about changes in the company's board of directors and senior management, as well as voting results from the annual meeting. There are no financial statements or detailed financial performance data present. The document is not an annual report, earnings release, or investor presentation. It is primarily an announcement of board and management changes and voting results. Therefore, the document fits best under the category of Board/Management Information (MANG) and Declaration of Voting Results & Voting Rights Announcements (DVA). However, since the document contains both the election of directors and voting results, the more comprehensive classification is Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings, including director elections. Confidence is high given the clear presence of voting results and director appointments in a Form 8-K filing.
2013-06-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 7, 2013, for OvaScience, Inc. It reports the election of a new director (Mary Fisher) and appointment of a new officer (Christopher M. Lindblom), including details of their compensation and agreements. It also includes the results of the 2013 annual meeting of stockholders, including votes on director elections and ratification of the independent auditor. The content focuses on changes in the board of directors and senior management, as well as voting results from the annual meeting. There is no comprehensive financial report or earnings data, so it is not an Annual Report (10-K) or Earnings Release (ER). The document is not a proxy solicitation or presentation. The primary focus is on management and board changes, and voting results. Since it includes both management changes and voting results, the best classification is Board/Management Information (MANG) because the main emphasis is on the election and appointment of directors and officers, which is the core of Item 5.02 of Form 8-K. The voting results are included but are part of the broader management and board update. Confidence is high given the detailed descriptions of director and officer changes and related agreements.
2013-06-13 English
4
Director's Dealing
2013-06-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.